Aurobindo gets control of 7 Actavis plants in Europe

Indian drugmaker Aurobindo has completed its $41 million acquisition of 7 Actavis ($ACT) generic drug facilities across Western Europe. Aurobindo picked up facilities in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands. The deal included products, marketing authorizations and dossier license rights. They have also struck a long-term agreement for Aurobindo to provide Actavis with APIs. Release | More

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.